Improving communication and treatment adherence for Black breast cancer survivors
Improving Communication and Adherence in Black Breast Cancer Survivors
NA · Virginia Commonwealth University · NCT05334732
This study is testing a new program to help Black women with breast cancer communicate better with their doctors and stick to their treatment plans.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Virginia Commonwealth University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Washington D.C., District of Columbia and 2 other locations) |
| Trial ID | NCT05334732 on ClinicalTrials.gov |
What this trial studies
This study tests an intervention aimed at enhancing communication and adherence to systemic therapy among Black women diagnosed with breast cancer. The Sisters Informing Sisters (SIS) intervention includes survivor-led skill-building sessions and culturally tailored materials to empower participants in their medical encounters. The study will compare the effectiveness of the SIS intervention against enhanced usual care in a randomized controlled trial format, focusing on patient-centered communication and adherence to treatment. The goal is to address the disparities in breast cancer outcomes for Black women by improving their engagement with healthcare providers.
Who should consider this trial
Good fit: Ideal candidates for this study are Black women who are newly diagnosed with stage I-III breast cancer and have not yet started systemic therapy.
Not a fit: Patients who have previously received cancer treatment within the last two years or those who do not self-identify as Black may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve treatment adherence and outcomes for Black breast cancer survivors.
How similar studies have performed: Other studies have shown promise in using culturally tailored interventions to improve health outcomes in minority populations, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Self-identify as Black * Newly diagnosed (\~4 weeks post-definitive surgery and prior to initiation of adjuvant chemotherapy or endocrine therapy) patients (stage I-III) * Eligible for chemotherapy or endocrine therapy according to NCCN guidelines, but have not initiated systemic therapy * Ability to read and speak English * Ability to provide meaningful consent as determined by trained study personnel and/or a member of the patient's care team * No prior cancer treatment (other than skin cancer) in the two years preceding enrollment * Physicians Must be a license doctor of study patient(s) * Ability to speak English
Where this trial is running
Washington D.C., District of Columbia and 2 other locations
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia, United States (RECRUITING)
- MedStar Washington Hospital Center — Washington D.C., District of Columbia, United States (RECRUITING)
- Massey Cancer Center — Richmond, Virginia, United States (RECRUITING)
Study contacts
- Principal investigator: Vanessa B Sheppard, Ph.D — Virginia Commonwealth University
- Study coordinator: Vanessa B Sheppard, Ph.D
- Email: vanessa.sheppard@vcuhealth.org
- Phone: 804-682-2700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Black Women, Breast Cancer Survivor